Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Pagnoni

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Vaccine|March 8, 2017
Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodiesJanie Parrino, Shelly A McNeil, Steven J Lawrence, et al.
Vaccine|June 12, 2016
A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 monthsSven-Arne Silfverdal, Giancarlo Icardi, Timo Vesikari, et al.
The Pediatric Infectious Disease Journal|November 16, 2016
A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve MonthsTimo Vesikari, Thomas Becker, Andre F Vertruyen, et al.
Human Vaccines|October 29, 2010
Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years oldC Raina MacIntyre, Tony Egerton, Malcolm McCaughey, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Vaccine|March 8, 2017
Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodiesJanie Parrino, Shelly A McNeil, Steven J Lawrence, et al.
Vaccine|June 12, 2016
A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 monthsSven-Arne Silfverdal, Giancarlo Icardi, Timo Vesikari, et al.
The Pediatric Infectious Disease Journal|November 16, 2016
A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve MonthsTimo Vesikari, Thomas Becker, Andre F Vertruyen, et al.
Human Vaccines|October 29, 2010
Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years oldC Raina MacIntyre, Tony Egerton, Malcolm McCaughey, et al.
Pageof 3